CHINA RUYI Places Shrs at ~4.5% Discount to Raise ~HKD3.9B Net
Share Allotment Announcement: China Ruyi plans to issue 1.3 billion new shares at HKD3 each, representing approximately 7.51% of its enlarged issued share capital, with a discount to the previous closing price.
Use of Proceeds: The company aims to raise around HKD3.895 billion, allocating 20% for business growth, 60% for strategic investments and acquisitions, and 20% for general working capital.
Trade with 70% Backtested Accuracy
Analyst Views on 00136

No data
About the author

Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.

Market Performance: The HSI rose 146 points (0.5%) to 27,173, while the HSCEI and HSTECH also saw gains, with total market turnover reaching HKD133.823 billion.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN fell, while others like KUAISHOU and JD-SW experienced gains, indicating mixed performance in the tech sector.
AI and Chip Sector Trends: AI stocks remained in demand, with significant gains for companies like KNOWLEDGE ATLAS and MINIMAX-WP, while chip stocks showed varied results, with SMIC edging up and HUA HONG SEMI dipping.
Pharmaceutical Sector Gains: Drug manufacturers like CSPC PHARMA and INNOVENT BIO saw notable increases in their stock prices, reflecting positive momentum in the pharmaceutical industry.
Market Performance: The HSI rose by 224 points (0.9%) to 26,456, with significant gains in the HSCEI and HSTECH, while total market turnover reached HKD168.375 billion.
Regulatory Investigation: China's State Council's Anti-Monopoly and Anti-Unfair Competition Committee is investigating the food delivery platform service industry, impacting companies like MEITUAN-W.
Tech Stock Rally: AI and software stocks surged, with notable increases in companies like BIDU-SW and KUAISHOU-W, as anticipation builds for a new AI model release.
Automotive Market Outlook: The China Passenger Car Association forecasts flat sales for the car market this year, with several major carmakers experiencing declines in stock prices.

HKEX Tech 100 Index Launch: HKEX has introduced the HKEX Tech 100 Index, its first Hong Kong equity index, which tracks 100 major Hong Kong-listed companies across six innovative sectors, including AI and biotech.
Accessibility for Investors: The index allows for Stock Connect Southbound trading, making it accessible to both global and Chinese Mainland investors, and includes a fast-entry mechanism for newly-listed companies.
Short Selling Data: The article provides detailed short selling data for various companies within the index, highlighting significant short selling ratios for several constituents.
Market Performance: The report includes stock performance changes for various companies, indicating fluctuations in share prices alongside their respective short selling activities.
Market Overview: The HSI fell 45 points to 24,727, with notable declines in technology stocks like Tencent and SMIC, while logistics stocks such as ZTO Express saw significant gains.
Company Highlights: Meituan, Taobao Instant Commerce, Ele.me, and JD.com called for a boycott against disorderly competition; meanwhile, NIO's stock surged by over 9% due to positive delivery forecasts.
Share Allotment Announcement: China Ruyi plans to issue 1.3 billion new shares at HKD3 each, representing approximately 7.51% of its enlarged issued share capital, with a discount to the previous closing price.
Use of Proceeds: The company aims to raise around HKD3.895 billion, allocating 20% for business growth, 60% for strategic investments and acquisitions, and 20% for general working capital.








